Malignant Neoplasm of Breast Clinical Trial
— CAELYXOfficial title:
A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced HER2
positive pretreated Breast Cancer.
Treatment Plan:
Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is
administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is
defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib
1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30
mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die. Three
patients will be initially enrolled in each dose level starting from level 1. If none of the
first triplet of patients will develop DLT, the dose will be escalated to the next level for
the subsequent three patients. If one of the first triplets of patients will develop
first-course DLT, a maximum of 3 additional patients will be entered at the same dose level.
The MTD is defined as the dose below that at which two patients have experienced DLT.
Lapatinib will be self-administered by the patient in an outpatient setting at the dose of
the assigned step. Patients will take the drug daily by mouth on days 1 to 21 of each cycle.
Caelyx will be administered by intravenous infusion over an exact period of 1 hour
(preferably by a pump to guarantee a constant speed of infusion) on day
1 of each cycle repeated every 21 days.
STATISTICAL METHODOLOGY:
Evaluation of toxicity: all patients will be evaluable for toxicity from the time of their
first treatment with Caelyx and Lapatinib.
Evaluation of response: all patients included in the study must be assessed for response to
treatment, even if there are major protocol treatment deviations or if they are ineligible.
All conclusions should be based on all eligible patients. Subanalyses may then be performed
on the basis of a subset of patients, excluding those for whom major protocol deviations
have been identified .However, these subanalyses may not serve as the basis for drawing
conclusions concerning treatment efficacy, and the reasons for excluding patients from the
analysis should be clearly reported. The 95% confidence intervals should also be provided.
Status | Terminated |
Enrollment | 11 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female patients with histologically or cytologically confirmed diagnosis of breast cancer. - Locally advanced (Stage IIIb or Stage IIIc with T4 lesion) or metastatic (Stage IV) disease. - Subjects must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to study entry. - Subjects must have disease progression (by RECIST) following prior therapy with taxane and trastuzumab-containing regimens (if not contraindicated). - Patients may have had any number of prior chemotherapy, immunotherapy, hormonal therapy, investigational or radiotherapy regimens, but therapy must be discontinued at least 4 weeks before study entry (6 weeks if the last regimen included BCNU or mitomycin C). - Age >18 years. - Life expectancy of greater than 12 weeks. - ECOG performance status <2 (see Appendix A). - Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram (ECHO). - Previous anthracycline use inferior of 360 mg/mq for epirubicin and 200 mg/mq for doxorubicin (provided that patients have been off-treatment for at least one year and did not progress under treatment). - Patients must have normal organ and marrow function as defined below: - leukocytes >3,000/mL - absolute neutrophil count >1,500/mL - platelets >100,000/mL - total bilirubin < 1.5 X institutional upper limit of normal - AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal (= 5 in patients with liver metastases) - creatinine < 1.5 X institutional upper limit of normal - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - Ability to swallow and retain oral medications. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Participation in another clinical trial with any investigational agents within 30 days prior to study screening. - Prior treatment with Caelyx or Lapatinib. - Previous malignancy except cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors, or other malignancies curatively treated > 3 years before study entry. - Patients with symptomatic brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction, that would confound the evaluation of neurologic and other adverse events. Asymptomatic patients are allowed. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to Caelyx and Lapatinib or other agents used in the study. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment); - Malabsorption syndrome or any disease significantly affecting gastrointestinal function. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | UO Oncologia medica, IRCCS IRST | Meldola | FC |
Lead Sponsor | Collaborator |
---|---|
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD (Maximum Tolerated Dose) | The MTD (Maximum Tolerated Dose) is defined as the dose below that at which two patients have experienced DLT (Dose Limiting Toxicity). | 6 years | Yes |
Secondary | Anti tumour activity of Lapatinib in combination with Caelyx in terms of Objective Response Rate (CR or PR). | Response and progression are evaluated using the RECIST Criteria (Response Evaluation Criteria In Solid Tumors). | 6 years | No |
Secondary | Evaluation of toxicity. | All patients will be evaluable for toxicity from the time of their first treatment with Caelyx and Lapatinib, using NCI-CTCAE v.3 (National cancer Institute - Common Terminology Criteria for Adverse Events). | 6 years. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
Completed |
NCT01953003 -
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
Not yet recruiting |
NCT01395706 -
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
|
Phase 2 | |
Enrolling by invitation |
NCT05486520 -
Low-field MRI for Breast Cancer Screening
|
N/A | |
Completed |
NCT05159778 -
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
|
Phase 2 | |
Active, not recruiting |
NCT03379428 -
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
Withdrawn |
NCT03261323 -
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
|
N/A | |
Recruiting |
NCT04669873 -
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
|
N/A | |
Completed |
NCT02408393 -
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
|
Phase 3 | |
Completed |
NCT03289819 -
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
|
Phase 2 | |
Completed |
NCT02495363 -
Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
|
||
Completed |
NCT03159195 -
Ibrance Real World Insights
|
||
Completed |
NCT03425656 -
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05033756 -
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
|
Phase 2 | |
Not yet recruiting |
NCT01641003 -
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|
N/A | |
Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
Active, not recruiting |
NCT02204098 -
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
|
Phase 1 | |
Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 |